Brief: Helix Biopharma Reports Q1 Loss Per Share C$0.02

Helix Biopharma

13/12/2019 12:51

Dec 13 (Reuters) - Helix Biopharma Corp  HBP.TO :
    * . ANNOUNCES FISCAL FIRST QUARTER 2020 RESULTS
    * Q1 LOSS PER SHARE C$0.02
    * HELIX BIOPHARMA - HAS BEEN IN DISCUSSIONS WITH CAPITAL
MARKET
FIRMS TO RAISE CAPITAL TO QUALIFY FOR A LISTING ON A U.S. STOCK
EXCHANGE
    * HELIX BIOPHARMA - CO'S CASH RESERVES AS OF OCT 31, ARE
INSUFFICIENT TO MEET ANTICIPATED CASH NEEDS THROUGH NEXT TWELVE
MONTHS
    * HELIX BIOPHARMA - CONSIDERS SECURING ADDITIONAL FUNDS,
PRIMARILY
THROUGH ISSUANCE OF EQUITY SECURITIES, TO BE CRITICAL FOR
DEVELOPMENT NEEDS
    * HELIX BIOPHARMA - CO'S CASH RESERVES AS OF OCT 31 ARE ALSO
INSUFFICIENT TO SEE PLANNED RESEARCH AND DEVELOPMENT INITIATIVES
THROUGH TO COMPLETION

Source text for Eikon:  ID:nGNX1Jj3s7 
Further company coverage:  HBP.TO 

 ((Reuters.Briefs@thomsonreuters.com;))